Shares of AVEO Oncology (AVEO) jumped about 20% in extended trading hours Wednesday after the company announced that the FDA approved Fotivda (tivozanib) for the treatment of patients with relapsed or refractory advanced renal cell carcinoma.
Fotivda is the first therapy approved for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies. The company plans to make the treatment available to patients in the U.S. by March 31, 2021.
Fotivda is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
The approval of Fotivda was based on AVEO's pivotal Phase 3 study, TIVO-3, comparing Fotivda to sorafenib in relapsed or refractory advanced RCC following two or more prior systemic therapies. The application is also supported by three additional trials in RCC and includes safety data from over 1,000 clinical trial subjects.
AVEO closed Wednesday's trading at $15.28, up $7.20 or 89.11%, on the Nasdaq. The stock further gained $3.08 or 20.16% in the after-hours trade.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.